Michelle Werner

Michelle Werner joined Ipsen in March 2026 as Executive Vice President and President of North America.

Prior to Ipsen, Michelle served as CEO-Partner at Flagship Pioneering and President and CEO of Alltrna, a tRNA platform company. During her tenure at Alltrna, she built and led a team that unlocked the biology of a brand new modality and advanced the first-ever tRNA therapeutic toward human trials. Michelle also previously served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology, where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts resulting in a doubling of long-term portfolio value for the franchise. Before Novartis, Michelle was a senior leader at AstraZeneca and as Global Franchise Head in Hematology, she was critical in launching multiple indications worldwide for CALQUENCE®. Prior to this, Michelle was Head of US Oncology, where she led the business through dramatic growth in both team and revenue through eight-plus product launches. Before AstraZeneca, Michelle was with Bristol-Myers Squibb for 10 years in various positions of increasing responsibility including roles in sales, marketing, and market access in the U.S. and UK, and above market in Europe (based in France) and global almost exclusively in oncology. Michelle started her professional career in R&D, working hands-on with patients at the Oncology Clinical Trials Unit at Harvard Medical School before moving into industry in clinical operations.

Outside of her corporate responsibilities, Michelle is a wife and mother to three children and is a member of the rare disease community. She is currently serving Board appointments for the non-profit organizations Rare Disease Renegades and Cure Rare Disease, a purpose that fuels her passions both personally and professionally.